CGTX

Cognition Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cogrx.com
Employees(FY) 22
ISIN US19243B1026

Performance

+23.89%

+41.91%

+3.4%

-68.65%

-65.94%

YTD

-62.27%

Profile

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease. The company is also developing COG0201 SHINE, a randomized double-blind and placebo-controlled for mild-to-moderate AD and is in phase II clinical trial. Its product pipeline also includes CT2168 for Synucleinopathies; and CT2074 for dry age-related macular degeneration. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Advanced Technical Analysis

Technical Analysis of CGTX 2024-12-20

The stock exhibits a bullish sentiment overall, with a strong Moving Average Score of 76 indicating positive momentum, while the Technical Score of 63 further supports this outlook. However, the Oscillators Score of 50 suggests a neutral stance, indicating potential consolidation or indecision in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CGTX

Stock Rank

Recent News & Updates

2024-12-19 18:21
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data(Yahoo Finance)
2024-12-18 18:31
Cognition Therapeutics announces results in Phase 2 study of CT1812(Yahoo Finance)
2024-12-17 18:22
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies(Globenewswire)
2024-11-27 20:55
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now(Yahoo Finance)
2024-11-25 18:40
Cognition Therapeutics provided an update on Phase 2 SHINE study analysis(Yahoo Finance)
2024-11-25 18:30
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies(Globenewswire)
2024-11-24 18:30
Cognition Therapeutics' Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer's Population(Globenewswire)
2024-11-14 19:35
Life Sciences Investor Forum: Presentations Now Available for Online Viewing(Yahoo Finance)
2024-11-12 18:30
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update(Globenewswire)
2024-11-11 19:35
Life Sciences Investor Forum Agenda Announced for November 14th(Yahoo Finance)
2024-11-11 18:30
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum(Globenewswire)
2024-10-31 04:15
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD(Globenewswire)
2024-10-29 00:55
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD(Globenewswire)
2024-10-22 19:30
Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD(Globenewswire)
2024-10-21 19:30
Cognition Therapeutics Releases New Episode of Conversations Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)(Globenewswire)
2024-10-09 05:37
Cognition Therapeutics Inc (CGTX) Q2 2024 Earnings Call Highlights: Promising Alzheimer's Trial ...(Yahoo Finance)
2024-10-01 19:30
Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference(Globenewswire)
2024-09-30 19:30
Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia(Globenewswire)
2024-09-02 19:30
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences(Globenewswire)
2024-08-21 19:31
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease(Globenewswire)
2024-08-07 19:00
Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update(Globenewswire)
2024-08-04 19:30
Cognition Therapeutics to Report Second Quarter 2024 Financial Results(Globenewswire)
2024-07-29 18:32
Cognition Therapeutics stock dips 43% following trial results for Alzheimers candidate(Yahoo Finance)
2024-07-28 23:58
Tivic Health Systems (TIVC) Stock Pops Another 39%(Investorplace)
2024-07-28 19:00
Cognition Therapeutics' Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer's Patients(Globenewswire)
2024-07-26 04:11
Cognition Therapeutics to Host Investor Webcast to Discuss Results from Proof-of-Concept Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at 8:30am ET on Monday July 29, 2024(Globenewswire)
2024-07-01 19:30
Results from Cognition Therapeutics' Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's Disease Accepted for Presentation at AAIC(Globenewswire)
2024-05-20 19:30
Cognition Therapeutics Releases New Episode of Conversations Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease(Globenewswire)
2024-05-07 01:53
CGTX Stock Earnings: Cognition Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-06 19:30
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update(Globenewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.